Validating the Core Set for Vocational Rehabilitation in a Population of Cancer Survivors: A Cross-Sectional Study.
Sara Paltrinieri, Martina Pellegrini, Stefania Costi and 4 others
PMID 39663312WHAT IT FOUND
The CS-VR-Onco checklist successfully mapped return-to-work difficulties in 104 cancer survivors.
It identified more problems in patients who reported difficulty returning to work and in those who had chemotherapy, confirming it can help target vocational rehabilitation.
Key findings
01The tool detected differences between survivors who reported return-to-work difficulties and those who did not, with the former group reporting more problems across all components.
02Survivors who had undergone chemotherapy reported more problems than those who had not, supporting the tool's ability to identify a known risk group for return-to-work difficulties.
03The assessment was feasible, with all participants answering every question in an average interview time of 47 minutes.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
There was no gold standard to validate the tool against, so validity was assessed by checking if it could distinguish between known groups (those with vs without perceived difficulties, and those with vs without chemotherapy). The study only included survivors who had successfully returned to work, so the tool may not capture barriers relevant to those who lost their jobs or have not yet returned. Interviews occurred 3-4 years after diagnosis, introducing potential recall bias regarding earlier return-to-work difficulties. The average interview length of 47 minutes may be too long for routine clinical settings.
Declared interests
No specific funding sources or author conflicts of interest were declared in the provided text.
The easy way to misread this
Do not interpret the validation as proof that the CS-VR-Onco improves patient outcomes or return-to-work rates. It only shows the tool can reliably describe and distinguish between different levels of perceived difficulty and treatment history.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →